Primary Prevention of Atherosclerotic Cardiovascular DiseasePhase 3NCT05739383
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
A Phase 3 study testing Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL in people with Primary Prevention of Atherosclerotic Cardiovascular Disease, run by Novartis Pharmaceuticals at 983 sites in 42 countries.
Trial summary
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease… Read more about this study
- Who is it for?
- Ages 40 to 79 years
- Conditions the study is for
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- What is being tested?
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 14,012 participants
- Where
- 983 sitesin 42 countries
- Study dates
- 9 Mar 2023to 16 Apr 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- At an increased risk for a first MACE (i.e., no prior major ASCVD event), defined as any one of the following:
- Evidence of atherosclerotic coronary artery disease (CAD) on computer tomography (CT) or invasive coronary angiogram defined as a coronary artery stenosis ≥20% but <50% in the left main coronary artery or stenosis ≥20% but <70% in any other major epicardial coronary artery, or
- Coronary artery calcium (CAC) score obtained by CT-scan ≥100 Agatston units, or
- High 10-year ASCVD risk ≥20%, or
- Intermediate 10-year ASCVD risk 7.5% - <20% with at least 2 risk-enhancing factors.
- LDL-C ≥70 mg/dL (≥1.81 mmol/L) but <190 mg/dL (<4.91 mmol/L) at the screening visit. If on a background lipid lowering therapy, the dose should be stable for at least 4 weeks prior to the screening visit and the participant should be willing to remain on this background therapy for the entire duration of the study.
Who cannot join
- History of major ASCVD event.
- History of, or planned, ischemia-driven revascularization in a coronary or extracoronary arterial bed prior to randomization
- Absence of coronary atherosclerosis on a CT angiogram or an invasive coronary angiogram in the 2 years prior to randomization
- Coronary artery calcium (CAC) score of 0 obtained in the 2 years prior to randomization
- Active liver disease or hepatic dysfunction
- Previous, current, or planned treatment with a monoclonal antibody (mAb) directed toward proprotein convertase subtilisin/kexin type 9 (PCSK9) (e.g., evolocumab, alirocumab)
Show all 9Show fewer
- Pregnant or nursing (lactating) women
- Women of childbearing potential unless they are using effective methods of contraception while taking study treatment which includes for 6 months after last study drug administration
- Other protocol-defined inclusion/exclusion criteria may apply.
Trial locations and contacts
983 sites in 42 countries.
983 sites in 42 countries
United States241 sites
Albany Medical College
Albany, New York, 12206
Capital Cardiology Associates
Albany, New York, 12211
Pharma Tex Research
Amarillo, Texas, 79106
Amarillo Heart Clin Rsh Inst
Amarillo, Texas, 79124
Endeavor Health Clinical Op- NCH
Arlington Heights, Illinois, 60005
Ascension Saint Agnes Heart Care
Baltimore, Maryland, 21229
Northeast Cardiology Associates
Bangor, Maine, 04401
North Hills Medical Research Inc
Bedford, Texas, 76021
Metropolitan Cardiovascular Consultants Llc
Beltsville, Maryland, 20705
Cardiovascular Res Found
Beverly Hills, California, 90210
National Heart Institute
Beverly Hills, California, 90211
Central Alabama Research
Birmingham, Alabama, 35209
UAB St Vincents
Birmingham, Alabama, 35211
Excel Medical Clinical Trials LLC
Boca Raton, Florida, 33434
MGH
Boston, Massachusetts, 02114-2696
Graves Gilbert Clinic
Bowling Green, Kentucky, 42101
Nova Clinical Research LLC
Bradenton, Florida, 34209
Advanced Heart Care
Bridgewater, New Jersey, 08807
Burke Internal Medicine and Research
Burke, Virginia, 22015
Mercury Street Medical
Butte, Montana, 59701
Alliance Clinical
Canoga Park, California, 91303
East Coast Research
Canton, Georgia, 30114
Aultman Hospital
Canton, Ohio, 44710
Cary Research Group
Cary, North Carolina, 27511
Chicago Clinical Research Inst
Chicago, Illinois, 60607
University of Illinois at Chicago
Chicago, Illinois, 60612
Inland Psychiatric Medical Group
Chino, California, 91710
Synexus Clinical Research US Inc
Cincinnati, Ohio, 45236
StudyMetrix Research
City of Saint Peters, Missouri, 63303
Bay Care Medical Group
Clearwater, Florida, 33756
Clearwater Cardiovascular and Interventional Consultants
Clearwater, Florida, 33756
Tampa Bay Medical Research
Clearwater, Florida, 33761
Johns Hopkins University
Columbia, Maryland, 21044
Columbia VA Health Care System
Columbia, South Carolina, 29209
West Broadway Clinic
Council Bluffs, Iowa, 51501
Valley Clinical Trials Inc
Covina, California, 91723
Cardiovascular Associates Research
Covington, Louisiana, 70433
Louisiana Heart Center Research
Covington, Louisiana, 70433
Avant Research Associates LLC
Crowley, Louisiana, 70526
Clinical Research Solution
Cypress, Texas, 77429
VA North Texas Health Care System
Dallas, Texas, 75216
Zenos Clinical Research
Dallas, Texas, 75230
SW Family Medicine Associates
Dallas, Texas, 75235
Primed Clinical Research
Dayton, Ohio, 45429
Providence Medical Group
Dayton, Ohio, 45439
Cardiology Research Associates
Daytona Beach, Florida, 32117
Hillcrest Medical Research
DeLand, Florida, 32720
Personal Physicians Care
Delray Beach, Florida, 33445
Henry Ford Hospital
Detroit, Michigan, 48202
Essentia Health
Duluth, Minnesota, 55805
David Turbay MD PLLC
El Paso, Texas, 79905
Beacon Health System
Elkhart, Indiana, 46514
Cardiovas Assoc of Delaware Valley
Elmer, New Jersey, 08318
Eastern Shore Research Institute
Fairhope, Alabama, 36532
Virginia Heart
Falls Church, Virginia, 22042
Lillestol Research LLC
Fargo, North Dakota, 58103
Javara Research
Fayetteville, Georgia, 30214
Fleming Island Ctr Clinical Res.
Fleming Island, Florida, 32003
AA Medical Research Center
Flint, Michigan, 48504
New York Presbyterian Queens
Flushing, New York, 11355
G and L Research LLC
Foley, Alabama, 36535
Proactive Clinical Research
Fort Lauderdale, Florida, 33308
Texas Health Physicians Group
Fort Worth, Texas, 76107
Anderson Medical Research
Ft. Washington, Maryland, 20744
Synexus
Glendale, Arizona, 85306
Lenzmeier Family Practice
Glendale, Arizona, 85308
Altru Health Research Dept.
Grand Forks, North Dakota, 58201
Medication Management LLC
Greensboro, North Carolina, 27401
Moses Cone Hospital
Greensboro, North Carolina, 27401
Bon Secours Medical Group
Greenville, South Carolina, 29607
Wellmont CVA Heart Institute
Greenville, Tennessee, 37745
TRIBE Clinical Research
Greer, South Carolina, 29651
Las Vegas Endocrinology
Henderson, Nevada, 89074
Qway Research
Hialeah, Florida, 33010
Sister Life Research Inc
Hialeah, Florida, 33013
Center for Diabetes and Endocrine Care
Hollywood, Florida, 33021
South Florida Rsrch Solutions LLC
Hollywood, Florida, 33021
Zenith Clinical Research
Hollywood, Florida, 33021
Encore Medical Research
Hollywood, Florida, 33024
East West Research Institute
Honolulu, Hawaii, 96814
Heart Care Associates P C
Hopewell, Virginia, 23860
CCT Hatboro Medical Associates
Horsham, Pennsylvania, 19044
East Texas Cardiology PA
Houston, Texas, 77002
Primecare Medical Group
Houston, Texas, 77024
Northwest Houston Cardiology PA
Houston, Texas, 77070
MedCare Pharma LLC
Houston, Texas, 77079
Dallas Heart and Vascular Consultants PA
Houston, Texas, 77084
Longwood Research
Huntsville, Alabama, 35801
Hutchinson Clinic
Hutchinson, Kansas, 67502
Elite Clinical Research LLC
Jackson, Mississippi, 39202
Jackson Heart Clinic
Jackson, Mississippi, 39216
VAMC Research-G V Sonny Montgomery Clinic
Jackson, Mississippi, 39216
Apex Cardiology Research Associates of Jackson
Jackson, Tennessee, 38301
UF Health Science Center
Jacksonville, Florida, 32209
East Coast Institute for Research
Jacksonville, Florida, 32216
Kansas City VA Medical Center
Kansas City, Missouri, 64128
Holston Medical Group
Kingsport, Tennessee, 37660
Texas Cardiology Assocs Of Houston
Kingwood, Texas, 77339
New Phase Research And Development
Knoxville, Tennessee, 37909
Accellacare
Knoxville, Tennessee, 37938
Trident Cardiology
Ladson, South Carolina, 29465
Capitol Cardiology Associates
Lanham, Maryland, 20706
AB Clinical Trials
Las Vegas, Nevada, 89119
Clinical Research of South Nevada
Las Vegas, Nevada, 89121
Epic Clinical Research
Lewisville, Texas, 75057
The Research Group
Lexington, Kentucky, 40503
NexGen Research
Lima, Ohio, 45801
Nebraska Heart Institute
Lincoln, Nebraska, 68510
Lincoln Internal Medicine Associates
Lincoln, Nebraska, 68516
New Jersey Heart
Linden, New Jersey, 07036
Main Street Physicians Care
Little River, South Carolina, 29566
South Denver Cardiology Associates PC
Littleton, Colorado, 80120
East Texas Research Associates Inc.
Livingston, Texas, 77351
Keck Medical Center USC
Los Angeles, California, 90033
Charles R Drew University of Medicine and Science
Los Angeles, California, 90059
The Jones Center For Diabetes And Endocrine Wellness
Macon, Georgia, 31210
Carient Heart and Vascular
Manassas, Virginia, 20109
Manassas Clinical Research Center
Manassas, Virginia, 20110
North Shore Heart and Vascular
Mandeville, Louisiana, 70448
Rama Research LLC
Marion, Ohio, 43302
Bethesda Medical Clinic
Marrero, Louisiana, 70072
Doctors Hospital at Renaissance
McAllen, Texas, 78504
NOLA Care Clinical Research
Metairie, Louisiana, 70006
Omega Clinical Research
Metairie, Louisiana, 70006
Columbus Clinical Services LLC
Miami, Florida, 33125
Finlay Medical Research
Miami, Florida, 33126
Infinite Clinical Research
Miami, Florida, 33133
Springs Medical And Research
Miami, Florida, 33135
L and C Professional Medical Institute
Miami, Florida, 33144
Regenerate Clinical Trial
Miami, Florida, 33155
International Research Associates LLC
Miami, Florida, 33156
A and A Research Group Inc
Miami, Florida, 33186
Meridian International Research
Miami Gardens, Florida, 33014
Inpatient Research Clinical LLC
Miami Lakes, Florida, 33014
RM Medical Research Inc
Miami Lakes, Florida, 33014
Indago Research and Health Ctr Inc
Miami Lakes, Florida, 33016
MyMichigan Medical Center Midland
Midland, Michigan, 48670
Midwest Endocrinology Associates
Milwaukee, Wisconsin, 53215
Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407-3799
Eminat LLC
Miramar, Florida, 33027
CB Flock Corporation
Mobile, Alabama, 36608
West Virginia University Hospital
Morgantown, West Virginia, 26506
IMA Research
Mount Airy, North Carolina, 27030
Intermountain Medical Center
Murray, Utah, 84107
Mid Hudson Medical Research PLLC
New Windsor, New York, 12553
C for Endo Diabetes and MD
Newhall, California, 91321
Capital Area Research LLC
Newport, Pennsylvania, 17074
California Medical Research Associates Inc
Northridge, California, 91324
Valley Clinical Trials
Northridge, California, 91325
Lynn Health Science Institute
Oklahoma City, Oklahoma, 73106
South Oklahoma Heart Research LLC
Oklahoma City, Oklahoma, 73135
CCT Research
Omaha, Nebraska, 68130
University of Nebraska Med Center
Omaha, Nebraska, 68198
CV Ins of the South
Opelousas, Louisiana, 70570
Advent Health Orlando
Orlando, Florida, 32803
Research Integrity LLC
Owensboro, Kentucky, 42303
CTMD Research
Palm Springs, Florida, 33406
Stanford University Medical Center
Palo Alto, California, 94304
DBC Research USA
Pembroke Pines, Florida, 33029
Cardiovascular Services
Peoria, Illinois, 61602
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Fam Medical Specialists Of Fl Plc
Plant City, Florida, 33563
St Johns Center
Ponte Vedra, Florida, 32801
Peace River Cardiovascular Center
Port Charlotte, Florida, 33952
David M Headley Clinic
Port Gibson, Mississippi, 39150
Hudson Valley Urology
Poughkeepsie, New York, 12601
Cardiovascular Res of Knoxville LLC
Powell, Tennessee, 37849
MultiCare Ins Research Innovation
Puyallup, Washington, 98372
Multispecialty Research Ass Of NC
Raleigh, North Carolina, 27609
Care Access Research
Rapid City, South Dakota, 57701
Monument Health Clinical Research
Rapid City, South Dakota, 57701
Epic Medical Research
Red Oak, Texas, 75154
Synexus Clinical Research US Inc
Richfield, Minnesota, 55432
Virginia Commonwealth University
Richmond, Virginia, 23298-0111
Roanoke Heart Institute
Roanoke, Virginia, 24014
Rochester Clinical Research
Rochester, New York, 14609
Headlands Research Sacramento
Sacramento, California, 95821-2134
Cordova Clinical Research
Sacramento, California, 95841
Central Michigan University
Saginaw, Michigan, 48601
East Coast Inst for Research LLC
Saint Augustine, Florida, 32086
Park Nicollet Institute
Saint Louis Park, Minnesota, 55416
Fairview Health Services
Saint Paul, Minnesota, 55103
Northeast Clinical Research of San Antonio LLC
San Antonio, Texas, 78233
University of California San Diego
San Diego, California, 92103
Kaiser Permanente San Diego
San Diego, California, 92108
Acclaim Clinical Research
San Diego, California, 92120
San Diego Cardiac Center
San Diego, California, 92123
Kootenai Heart Clinic-Sandpoint
Sandpoint, Idaho, 83864
Diabetes And Endocrine Specialists
Sandy City, Utah, 84093
The Center for Clinical Trials
Saraland, Alabama, 36571
Cardiovascular Center Of Sarasota
Sarasota, Florida, 34239
Consano Clinical Research LLC
Shavano Park, Texas, 78231
Cardiovascular Solutions LLC
Shreveport, Louisiana, 71103
Louisiana Heart Center Research
Slidell, Louisiana, 70458
Frontier Clinical Research LLC
Smithfield, Pennsylvania, 15478
Encompass Clinical Research
Spring Valley, California, 91978
Heart House Research Foundation
Springfield, Ohio, 45504
Barnes Jewish Hosp-Washington Univ
St Louis, Missouri, 63110
St Louis V A Medical Center
St Louis, Missouri, 63125-4181
St Louis Heart and Vascular
St Louis, Missouri, 63136
Synexus Clinical Research US Inc
St Louis, Missouri, 63141
Advanced Medical Research Center
St. Petersburg, Florida, 33713
Cardiology Ass of Fairfield County
Stamford, Connecticut, 06905
Accellacare
Statesville, North Carolina, 28625
Javara Research
Stephenville, Texas, 76401
Centricity Research Suffolk Fam Med
Suffolk, Virginia, 23435
NRG Wellness Center
Sugarland, Texas, 77478
Clinical Research Inst of Arizona
Sun City West, Arizona, 85375
Universal Research Group LLC
Tacoma, Washington, 98405
James A Haley Veterans Hospital
Tampa, Florida, 33612
BayCare Health System
Tampa, Florida, 33705
Clinical Research Advantage Fiel Family and Sports Med, PC
Tempe, Arizona, 85283
Clinical Research Advantage
The Bronx, New York, 10468
Northwest Houston Clinical Research PLLC
Tomball, Texas, 77375
Cotton O Neil Clinical Res Center
Topeka, Kansas, 66606
Harbor UCLA Medical Center
Torrance, California, 90502
Troy Internal Medicine Research
Troy, Michigan, 48098
Atlanta Heart Specialists LLC
Tucker, Georgia, 30084
Synexus Clinical Research US Inc
Tucson, Arizona, 85741
Tennessee Center For Clinical Trials
Tullahoma, Tennessee, 37388
Cardiology Associates of North MS
Tupelo, Mississippi, 38801
Westchester Medical Center
Valhalla, New York, 10595
Buynak Clinical Research PC
Valparaiso, Indiana, 46383
Cardiology Associates Medical Group
Ventura, California, 93003
Blue Coast Research Center LLC
Vista, California, 92081
Care Access
Warwick, Rhode Island, 02886
Chase Medical Research LLC
Waterbury, Connecticut, 06708
Cardiovascular Research and Education Foundation Inc
Wausau, Wisconsin, 54401
Cardiology Partners Clinical Research Institute
Wellington, Florida, 33449
Confluence Health Hospital
Wenatchee, Washington, 98801
Comprehensive Center
Weslaco, Texas, 78596
Interv Cardiology Med Grp
West Hills, California, 91307
Monroe Research Llc
West Monroe, Louisiana, 71291
Great Lakes Medical Research
Westfield, New York, 14787
Kansas Nephrology Research Institute LLC
Wichita, Kansas, 67214
Adv Imaging Prev and Clin Research
Wilmington, North Carolina, 28401
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, 27157
Flourish Research
Winter Park, Florida, 32789
Umass Memorial Medical Center
Worcester, Massachusetts, 01655
Trinity Health Michigan Heart
Ypsilanti, Michigan, 48197
Southern Clinical Research
Zachary, Louisiana, 70791
Spain64 sites
Novartis Investigative Site
A Coruña, 15001
Novartis Investigative Site
A Coruña, 15006
Novartis Investigative Site
Alicante, 03700
Novartis Investigative Site
Almería, 04009
Novartis Investigative Site
Alzira, Valencia, 46600
Novartis Investigative Site
Antequera, Malaga, 29200
Novartis Investigative Site
Badalona, Barcelona, 08916
Novartis Investigative Site
Barcelona, Catalonia, 08003
Novartis Investigative Site
Barcelona, 08022
Novartis Investigative Site
Barcelona, 08023
Novartis Investigative Site
Barcelona, 08025
Novartis Investigative Site
Barcelona, 08028
Novartis Investigative Site
Barcelona, 08035
Novartis Investigative Site
Barcelona, 08041
Novartis Investigative Site
Boadilla del Monte, Madrid, 28660
Novartis Investigative Site
Cáceres, Extremadura, 10003
Novartis Investigative Site
Castilleja de la Cuesta, Sevilla, 41950
Novartis Investigative Site
Centelles, Barcelona, 08540
Novartis Investigative Site
Córdoba, 14004
Novartis Investigative Site
El Palmar, Murcia, 30120
Novartis Investigative Site
el Prat de Llobregat, Barcelona, 08820
Novartis Investigative Site
Elche, Alicante, 03203
Novartis Investigative Site
Ferrol, A Coruna, 15405
Novartis Investigative Site
Fuenlabrada, Madrid, 28942
Novartis Investigative Site
Granada, Andalusia, 18014
Novartis Investigative Site
Huelva, Andalusia, 21005
Novartis Investigative Site
Huelva, 21080
Novartis Investigative Site
La Roca del Vallès, Barcelona, 08430
Novartis Investigative Site
Las Palmas de Gran C, Las Palmas, 35016
Novartis Investigative Site
Las Palmas GC, 35010
Novartis Investigative Site
Lebrija, Sevilla, 41570
Novartis Investigative Site
Madrid, 28003
Novartis Investigative Site
Madrid, 28009
Novartis Investigative Site
Madrid, 28010
Novartis Investigative Site
Madrid, 28034
Novartis Investigative Site
Madrid, 28040
Novartis Investigative Site
Madrid, 28041
Novartis Investigative Site
Málaga, Andalusia, 29009
Novartis Investigative Site
Málaga, 29010
Novartis Investigative Site
Mallorca, Balearic Islands, 07198
Novartis Investigative Site
Marbella, Andalusia, 29600
Novartis Investigative Site
Mataró, Barcelona, 08303
Novartis Investigative Site
Palma, Balearic Islands, 07011
Novartis Investigative Site
Pamplona, Navarre, 31008
Novartis Investigative Site
Peralada, Girona, 17491
Novartis Investigative Site
Pozuelo de Alarcón, Madrid, 28223
Novartis Investigative Site
Puerto Real, Cadiz, 11510
Novartis Investigative Site
Reus, Tarragona, 43204
Novartis Investigative Site
Ronda, Malaga, 29400
Novartis Investigative Site
Salamanca, 37007
Novartis Investigative Site
San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320
Novartis Investigative Site
Sanlucar Barrameda, Cadiz, 11540
Novartis Investigative Site
Sant Adrià de Besòs, Barcelona, 08930
Novartis Investigative Site
Santander, Cantabria, 39008
Novartis Investigative Site
Santiago, A Coruna, 15702
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706
Novartis Investigative Site
Seville, 41009
Novartis Investigative Site
Seville, 41013
Novartis Investigative Site
Tarragona, 43002
Novartis Investigative Site
Utrera, Sevilla, 41710
Novartis Investigative Site
Valencia, 46014
Novartis Investigative Site
Vic, Barcelona, 08500
Novartis Investigative Site
Villamartín, Cadiz, 11650
Novartis Investigative Site
Zaragoza, 50009
United Kingdom45 sites
Novartis Investigative Site
Belfast, BT16 1RH
Novartis Investigative Site
Belfast, BT2 8BG
Novartis Investigative Site
Birmingham, B21 9RY
Novartis Investigative Site
Blackpool, FY3 8NR
Novartis Investigative Site
Bristol, South Gloucestershire, BS37 4AX
Novartis Investigative Site
Bristol, BS2 8HW
Novartis Investigative Site
Bury St Edmunds, Suffolk, IP33 2QZ
Novartis Investigative Site
Cardiff, Wales, CF23 9PN
Novartis Investigative Site
Cardiff, Wales, CF5 4AD
Novartis Investigative Site
Cardiff, CF64 2XX
Novartis Investigative Site
Chesterfield, S40 4AA
Novartis Investigative Site
Connor Downs, Cornwall, TR27 5DT
Novartis Investigative Site
Corby, Northamptonshire, NN17 2UR
Novartis Investigative Site
Denbighshire, LL18 1DA
Novartis Investigative Site
Dorchester, Dorset, DT1 2JY
Novartis Investigative Site
Edinburgh, EH16 4SA
Novartis Investigative Site
Exeter, Devon, EX2 5DW
Novartis Investigative Site
Fowey, Cornwall, PL23 1DT
Novartis Investigative Site
Glasgow, G20 7BE
Novartis Investigative Site
Hardwick, Stockton on Tees, TS19 8PE
Novartis Investigative Site
Harrow, Middlesex, HA1 3UJ
Novartis Investigative Site
High Wycombe, Buckinghamshire, HP11 2TT
Novartis Investigative Site
Kettering, NN16 8UZ
Novartis Investigative Site
Lancashire, FY4 3AD
Novartis Investigative Site
Liskeard, Cornwall, PL14 3XA
Novartis Investigative Site
London, GBR, EC1M 6BQ
Novartis Investigative Site
London, W12 0HS
Novartis Investigative Site
Londonderry, BT47 6SB
Novartis Investigative Site
Luton, Beds, LU4 0DZ
Novartis Investigative Site
Middlesex, TW7 6AF
Novartis Investigative Site
Newquay, Cornwall, TR7 1RU
Novartis Investigative Site
Norwich, NR4 7UY
Novartis Investigative Site
Peterborough, Cambridgeshire, PE3 9GZ
Novartis Investigative Site
Plymouth, PL5 3JB
Novartis Investigative Site
Plympton, PL7 2QP
Novartis Investigative Site
Portadown, Nothern Ireland, BT63 5QQ
Novartis Investigative Site
Rhyl, LL18 5UJ
Novartis Investigative Site
Salford, M6 8HD
Novartis Investigative Site
Scunthorpe, DN15 7BH
Novartis Investigative Site
Sheffield, S5 7AU
Novartis Investigative Site
Tyne and Wear, NE29 8NH
Novartis Investigative Site
Wansford, Peterborough, PE8 6PL
Novartis Investigative Site
Wiltshire, SN15 2SB
Novartis Investigative Site
Wirrel, CH62 6EE
Novartis Investigative Site
Wrexham, LL13 7TD
Argentina44 sites
Novartis Investigative Site
Buenos Aires, C1114AAP
Novartis Investigative Site
Buenos Aires, C1428DCO
Novartis Investigative Site
Buenos Aires, W3400ABH
Novartis Investigative Site
Caba, Buenos Aires, C1119ACN
Novartis Investigative Site
Caba, C1015ABO
Novartis Investigative Site
Caba, C1427CCL
Novartis Investigative Site
CABA, Buenos Aires, 1425
Novartis Investigative Site
CABA, Buenos Aires, C1221ADC
Novartis Investigative Site
CABA, Buenos Aires, C1280AEB
Novartis Investigative Site
CABA, Buenos Aires, C1405BCH
Novartis Investigative Site
CABA, Buenos Aires, C1406BOA
Novartis Investigative Site
CABA, Buenos Aires, C1407FWE
Novartis Investigative Site
CABA, Buenos Aires, C1414AIF
Novartis Investigative Site
CABA, Buenos Aires, C1425AGC
Novartis Investigative Site
CABA, Buenos Aires, C1426ABP
Novartis Investigative Site
Capital Federal, C1023AAB
Novartis Investigative Site
Concepcion Uruguay, Entre Ríos Province, E3260EPD
Novartis Investigative Site
Córdoba, Córdoba Province, X5000AAW
Novartis Investigative Site
Córdoba, Córdoba Province, X5000
Novartis Investigative Site
Córdoba, Córdoba Province, X5003DCE
Novartis Investigative Site
Córdoba, Córdoba Province, X5003DCP
Novartis Investigative Site
Córdoba, Córdoba Province, X5016KEH
Novartis Investigative Site
Córdoba, X5000JHA
Novartis Investigative Site
Córdoba, X5000JHQ
Novartis Investigative Site
Córdoba, X5002HWE
Novartis Investigative Site
Corrientes, 3400
Novartis Investigative Site
Formosa, Formosa Province, P3600MPD
Novartis Investigative Site
Grandero Baigorria, Santa Fe Province, S2152
Novartis Investigative Site
Lanus, Buenos Aires, B8000XAV
Novartis Investigative Site
Mar del Plata, Buenos Aires, B7600ENA
Novartis Investigative Site
Mendoza, Mendoza Province, M5500AFD
Novartis Investigative Site
Paraná, Entre Ríos Province, 3100
Novartis Investigative Site
Ramos Mejía, Buenos Aires, B1704ETD
Novartis Investigative Site
Rosario, Santa Fe Province, S2000CVD
Novartis Investigative Site
Rosario, Santa Fe Province, S2000DBS
Novartis Investigative Site
Rosario, Santa Fe Province, S2000DSV
Novartis Investigative Site
Salta, Salta Province, A4406BPF
Novartis Investigative Site
San Luis, D5702JRS
Novartis Investigative Site
San Martín, Buenos Aires, B1650CSQ
Novartis Investigative Site
San Miguel, Tucumán Province, T4000IHE
Novartis Investigative Site
San Miguel de Tucumán, San Miguel de Tucuman, T4000ICL
Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, T4000IFL
Novartis Investigative Site
Santa Fe, Santa Fe Province, S3000FWO
Novartis Investigative Site
Santa Fe, S3000EOZ
China42 sites
Novartis Investigative Site
Beijing, 100083
Novartis Investigative Site
Beijing, 100730
Novartis Investigative Site
Cangzhou, Hebei, 061002
Novartis Investigative Site
Changsha, Hunan, 410005
Novartis Investigative Site
Changsha, Hunan, 410011
Novartis Investigative Site
Changzhou, Jiangsu, 213004
Novartis Investigative Site
Dalian, Liaoning, 116000
Novartis Investigative Site
Daqing, Heilongjiang, 163001
Novartis Investigative Site
Guangzhou, Guangdong, 510080
Novartis Investigative Site
Guangzhou, 510000
Novartis Investigative Site
Hangzhou, Zhejiang, 310000
Novartis Investigative Site
Hangzhou, Zhejiang, 310006
Novartis Investigative Site
Harbin, Heilongjiang, 150000
Novartis Investigative Site
Harbin, Heilongjiang, 150001
Novartis Investigative Site
Hohhot, Inner Mongolia, 010017
Novartis Investigative Site
Huangshi, Hubei, 435000
Novartis Investigative Site
Jinan, Shandong, 250021
Novartis Investigative Site
Jining, Shandong, 272000
Novartis Investigative Site
Jining, 272011
Novartis Investigative Site
Jinzhou, Liaoning, 121001
Novartis Investigative Site
Lishui, Zhejiang, 323020
Novartis Investigative Site
Luoyang, Henan, 471002
Novartis Investigative Site
Nanchang, Jiangxi, 330009
Novartis Investigative Site
Nanning, Guangxi, 530022
Novartis Investigative Site
Pingdingshan, Henan, 467000
Novartis Investigative Site
Qingdao, Shandong, 266011
Novartis Investigative Site
Shanghai, 200120
Novartis Investigative Site
Shenyang, Liaoning, 110016
Novartis Investigative Site
Shijiazhuang, Hebei, 050000
Novartis Investigative Site
Tangshan, Hebei, 063000
Novartis Investigative Site
Tianjin, Tianjin Municipality, 300121
Novartis Investigative Site
Tianjin, 300140
Novartis Investigative Site
Tonghua, Jilin, 134000
Novartis Investigative Site
Wenzhou, Zhejiang, 325000
Novartis Investigative Site
Wuhan, Hubei, 430081
Novartis Investigative Site
Xian, Shanxi, 710061
Novartis Investigative Site
Xianyang, Shaanxi, 712000
Novartis Investigative Site
Xingtai, Hebei, 054000
Novartis Investigative Site
Xuzhou, Jiangsu, 221003
Novartis Investigative Site
Yinchuan, Ningxia, 750004
Novartis Investigative Site
Zhengzhou, Henan, 450003
Novartis Investigative Site
Zibo, Shandong, 255000
India35 sites
Novartis Investigative Site
Ahmedabad, Gujarat, 380054
Novartis Investigative Site
Ahmedabad, Gujarat, 380060
Novartis Investigative Site
Ajmer, Rajasthan, 305001
Novartis Investigative Site
Bangalore, Karnataka, 560069
Novartis Investigative Site
Belagavi, Karnataka, 590010
Novartis Investigative Site
Bikaner, Rajasthan, 334003
Novartis Investigative Site
Chennai, Tamil Nadu, 600081
Novartis Investigative Site
Chennai, Tamil Nadu, 600116
Novartis Investigative Site
Coimbatore, Tamil Nadu, 641009
Novartis Investigative Site
Coimbatore, Tamil Nadu, 641037
Novartis Investigative Site
Coimbatore, 641018
Novartis Investigative Site
Dehradun, Uttarakhand, 248001
Novartis Investigative Site
Dehradun, Uttrakhand, 248104
Novartis Investigative Site
Guntur, Andhra Pradesh, 522001
Novartis Investigative Site
Jaipur, Rajasthan, 302001
Novartis Investigative Site
Jaipur, Rajasthan, 302020
Novartis Investigative Site
Kanpur, Uttar Pradesh, 208002
Novartis Investigative Site
Kochi, Kerala, 682018
Novartis Investigative Site
Kochi, Kerala, 682041
Novartis Investigative Site
Kolkata, West Bengal, 700020
Novartis Investigative Site
Lucknow, Uttar Pradesh, 226003
Novartis Investigative Site
Madurai, Tamil Nadu, 625020
Novartis Investigative Site
Mangalore, Karnataka, 575018
Novartis Investigative Site
Manipal, Karnataka, 576104
Novartis Investigative Site
Mysore, Karnataka, 570004
Novartis Investigative Site
Mysore, 570015
Novartis Investigative Site
Nagpur, Maharashtra, 440012
Novartis Investigative Site
Nagpur, Maharashtra, 441108
Novartis Investigative Site
Nashik, Maharashtra, 422005
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110002
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110060
Novartis Investigative Site
New Delhi, 110029
Novartis Investigative Site
Pune, Maharashtra, 411004
Novartis Investigative Site
Pune, Maharashtra, 411045
Novartis Investigative Site
Uttarakhand, 263153
Romania33 sites
Novartis Investigative Site
Afumaţi, Ilfov, 077010
Novartis Investigative Site
Baia Mare, Maramureş, 430123
Novartis Investigative Site
Baia Mare, Maramureş, 430222
Novartis Investigative Site
Brăila, 810325
Novartis Investigative Site
Brasov, 500283
Novartis Investigative Site
Bucharest, 010192
Novartis Investigative Site
Bucharest, 010496
Novartis Investigative Site
Bucharest, 010627
Novartis Investigative Site
Bucharest, 011055
Novartis Investigative Site
Bucharest, 011461
Novartis Investigative Site
Bucharest, 020475
Novartis Investigative Site
Bucharest, 021875
Novartis Investigative Site
Bucharest, 022328
Novartis Investigative Site
Buzău, Buzău, 120133
Novartis Investigative Site
Cluj-Napoca, Cluj, 400006
Novartis Investigative Site
Cluj-Napoca, 400001
Novartis Investigative Site
Cluj-Napoca, 400015
Novartis Investigative Site
Craiova, Dolj, 200513
Novartis Investigative Site
Craiova, Dolj, 200642
Novartis Investigative Site
Iași, 700544
Novartis Investigative Site
Oradea, Bihor County, 410001
Novartis Investigative Site
Piteşti, Argeş, 110424
Novartis Investigative Site
Suceava, Suceava, 720237
Novartis Investigative Site
Targoviste, Dâmbovița County, 130095
Novartis Investigative Site
Târgu Mureş, Mureș County, 540124
Novartis Investigative Site
Târgu Mureş, Mureș County, 540136
Novartis Investigative Site
Târgu Mureş, 540142
Novartis Investigative Site
Târgu Mureş, 540143
Novartis Investigative Site
Timișoara, Timiș County, 300041
Novartis Investigative Site
Timișoara, Timiș County, 300125
Novartis Investigative Site
Timișoara, Timiș County, 300362
Novartis Investigative Site
Timișoara, Timiș County, 300480
Novartis Investigative Site
Timișoara, Timiș County, 300723
Brazil32 sites
Novartis Investigative Site
Aracaju, Sergipe, 49055-530
Novartis Investigative Site
Belo Horizonte, Minas Gerais, 30150-320
Novartis Investigative Site
Belo Horizonte, Minas Gerais, 30430-142
Novartis Investigative Site
Blumenau, Santa Catarina, 89020-430
Novartis Investigative Site
Brasília, Federal District, 70390-700
Novartis Investigative Site
Brasília, Federal District, 70673-416
Novartis Investigative Site
Brasília, Federal District, 71625-009
Novartis Investigative Site
Campinas, São Paulo, 13060-080
Novartis Investigative Site
Campinas, 13092-133
Novartis Investigative Site
Canoas, Rio Grande do Sul, 92425-900
Novartis Investigative Site
Curitiba, Paraná, 80045-170
Novartis Investigative Site
Curitiba, Paraná, 80730-150
Novartis Investigative Site
Maceió, Alagoas, 57051-160
Novartis Investigative Site
Pelotas, Rio Grande do Sul, 96015-290
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90160-093
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90560-032
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90880-480
Novartis Investigative Site
Ribeirão Preto, São Paulo, 14048-900
Novartis Investigative Site
Rio de Janeiro, 20241-180
Novartis Investigative Site
Rio de Janeiro, 22270-060
Novartis Investigative Site
Salvador, Estado de Bahia, 40170-130
Novartis Investigative Site
Salvador, Estado de Bahia, 41810-011
Novartis Investigative Site
Santo André, São Paulo, 09030-010
Novartis Investigative Site
São José dos Campos, São Paulo, 12243-280
Novartis Investigative Site
Sao Jose Rio Preto, São Paulo, 15090-000
Novartis Investigative Site
São Paulo, São Paulo, 01321-001
Novartis Investigative Site
São Paulo, São Paulo, 01323-000
Novartis Investigative Site
São Paulo, São Paulo, 04012-909
Novartis Investigative Site
São Paulo, São Paulo, 04266-010
Novartis Investigative Site
Uberlândia, Minas Gerais, 38400-500
Novartis Investigative Site
Vitória, Espírito Santo, 29055-450
Novartis Investigative Site
Votuporanga, São Paulo, 15500-269
Czechia31 sites
Novartis Investigative Site
Brandýs nad Labem, 250 01
Novartis Investigative Site
Brno, 602 00
Novartis Investigative Site
Český Krumlov, 381 01
Novartis Investigative Site
Chlumec nad Cidlinou, 503 51
Novartis Investigative Site
Hlučín, 748 01
Novartis Investigative Site
Hodonín, 695 01
Novartis Investigative Site
Jihlava, 586 01
Novartis Investigative Site
Kolín, 280 20
Novartis Investigative Site
Liberec, 460 63
Novartis Investigative Site
Louny, Czech Republic, 440 01
Novartis Investigative Site
Mariánské Lázně, 353 01
Novartis Investigative Site
Náchod, 547 01
Novartis Investigative Site
Olomouc, 772 00
Novartis Investigative Site
Ostrava, Czech Republic, 725 27
Novartis Investigative Site
Ostrava, CZE, 728 80
Novartis Investigative Site
Ostrava, Zabreh, 700 30
Novartis Investigative Site
Ostrava, 710 00
Novartis Investigative Site
Pardubice, 532 03
Novartis Investigative Site
Plzen Bory, 301 00
Novartis Investigative Site
Prague, 100 34
Novartis Investigative Site
Prague, 104 00
Novartis Investigative Site
Prague, 128 08
Novartis Investigative Site
Prague, 148 00
Novartis Investigative Site
Prague, 158 00
Novartis Investigative Site
Přerov, Olomouc Region, 750 02
Novartis Investigative Site
Trutnov, 460 63
Novartis Investigative Site
Uherské Hradiště, 686 01
Novartis Investigative Site
Ústí nad Labem, Czech Republic, 400 01
Novartis Investigative Site
Ústí nad Labem, 400 01
Novartis Investigative Site
Zlín, 760 01
Novartis Investigative Site
Znojmo, 669 02
Canada29 sites
Novartis Investigative Site
Barrie, Ontario, L4N 7L3
Novartis Investigative Site
Brampton, Ontario, L6S 0C6
Novartis Investigative Site
Calgary, Alberta, T2H 2G4
Novartis Investigative Site
Edmonton, Alberta, T6K 4C1
Novartis Investigative Site
Etobicoke, Ontario, M9R 4E1
Novartis Investigative Site
Guelph, Ontario, N1H 1B1
Novartis Investigative Site
Halifax, Nova Scotia, B3H 2Y9
Novartis Investigative Site
Hamilton, Ontario, L8L 5G4
Novartis Investigative Site
Kelowna, British Columbia, V1Y 3J8
Novartis Investigative Site
Lévis, Quebec, G6W 5M6
Novartis Investigative Site
London, Ontario, N6A 5W9
Novartis Investigative Site
Mirabel, Quebec, J7J 2K8
Novartis Investigative Site
Moncton, New Brunswick, E1G 1A7
Novartis Investigative Site
Montreal, Quebec, H4A 3J1
Novartis Investigative Site
Napean, Ontario, K2J 0V2
Novartis Investigative Site
New Minas, Nova Scotia, B4N 3R7
Novartis Investigative Site
Newmarket, Ontario, L3Y 2P6
Novartis Investigative Site
North York, Ontario, M6B 3H7
Novartis Investigative Site
Oshawa, Ontario, L1J 2K9
Novartis Investigative Site
Québec, Quebec, G1V 4G5
Novartis Investigative Site
Québec, Quebec, G2J 0C4
Novartis Investigative Site
Red Deer, Alberta, T4P 1K4
Novartis Investigative Site
Scarborough Village, Ontario, M1B 5N1
Novartis Investigative Site
Terrebonne, Quebec, J6X 4P7
Novartis Investigative Site
Thornhill, Ontario, L4J 8L7
Novartis Investigative Site
Toronto, Ontario, M4G 3E8
Novartis Investigative Site
Trois-Rivières, Quebec, G9A 4P3
Novartis Investigative Site
Vancouver, British Columbia, V6Z 1Y6
Novartis Investigative Site
Victoriaville, Quebec, G6P 3Z8
Italy28 sites
Novartis Investigative Site
Ancona, AN, 60128
Novartis Investigative Site
Brescia, BS, 25123
Novartis Investigative Site
Caserta, CE, 81100
Novartis Investigative Site
Catanzaro, CZ, 88100
Novartis Investigative Site
Chiavari, GE, 16043
Novartis Investigative Site
Chieti, CH, 66100
Novartis Investigative Site
Cinisello Balsamo, MI, 20092
Novartis Investigative Site
Florence, FI, 50134
Novartis Investigative Site
Genova, GE, 16132
Novartis Investigative Site
Latina, LT, 04100
Novartis Investigative Site
Messina, ME, 98125
Novartis Investigative Site
Milan, MI, 20100
Novartis Investigative Site
Milan, MI, 20122
Novartis Investigative Site
Milan, MI, 20132
Novartis Investigative Site
Milan, MI, 20138
Novartis Investigative Site
Milan, MI, 20157
Novartis Investigative Site
Milan, MI, 20162
Novartis Investigative Site
Modena, MO, 41126
Novartis Investigative Site
Monza, MB, 20900
Novartis Investigative Site
Naples, 80131
Novartis Investigative Site
Naples, 80138
Novartis Investigative Site
Perugia, PG, 06129
Novartis Investigative Site
Pisa, PI, 56124
Novartis Investigative Site
Pisa, PI, 56126
Novartis Investigative Site
Pozzilli, IS, 86077
Novartis Investigative Site
Roma, RM, 00161
Novartis Investigative Site
Roma, RM, 00168
Novartis Investigative Site
Siena, SI, 53100
Mexico27 sites
Novartis Investigative Site
Actopan, Hidalgo, 42500
Novartis Investigative Site
Aguascalientes, 20116
Novartis Investigative Site
Aguascalientes, 20230
Novartis Investigative Site
Chihuahua City, 31238
Novartis Investigative Site
Cuernavaca, Morelos, 62250
Novartis Investigative Site
Culiacán, Sinaloa, 80200
Novartis Investigative Site
Culiacán, Sinaloa, 80230
Novartis Investigative Site
Distrito Federal, 03100
Novartis Investigative Site
Distrito Federal, 14080
Novartis Investigative Site
Guadalajara, Jalisco, 44260
Novartis Investigative Site
Guadalajara, Jalisco, 44340
Novartis Investigative Site
Guadalajara, Jalisco, 44670
Novartis Investigative Site
Gustavo Adolfo Madero, Mexico City, 07020
Novartis Investigative Site
León, Guanajuato, 37160
Novartis Investigative Site
Mérida, Yucatán, 97070
Novartis Investigative Site
Mexico City, Mexico City, 06700
Novartis Investigative Site
Mexico City, 06760
Novartis Investigative Site
Mexico D F, 06720
Novartis Investigative Site
Monterrey, Nuevo León, 64020
Novartis Investigative Site
Monterrey, Nuevo León, 64060
Novartis Investigative Site
Monterrey, Nuevo León, 64440
Novartis Investigative Site
Monterrey, Nuevo León, 64610
Novartis Investigative Site
Oaxaca City, 68020
Novartis Investigative Site
San Luis Potosí City, San Luis Potosí, 78200
Novartis Investigative Site
Tampico, Tamaulipas, 89440
Novartis Investigative Site
Tlalpan, Mexico City, 14050
Novartis Investigative Site
Veracruz, 91900
Poland26 sites
Novartis Investigative Site
Bialystok, 15-704
Novartis Investigative Site
Bydgoszcz, 85-048
Novartis Investigative Site
Bydgoszcz, 85-065
Novartis Investigative Site
Bygdoszcz, 85-605
Novartis Investigative Site
Chorzów, 41-500
Novartis Investigative Site
Elblag, 82-300
Novartis Investigative Site
Gdynia, 81-157
Novartis Investigative Site
Grudziądz, 86-300
Novartis Investigative Site
Katowice, 40-081
Novartis Investigative Site
Katowice, 40-555
Novartis Investigative Site
Katowice, 40-648
Novartis Investigative Site
Krakow, Maloposkie, 31-271
Novartis Investigative Site
Krakow, 30-721
Novartis Investigative Site
Krakow, 31-216
Novartis Investigative Site
Krakow, 31-501
Novartis Investigative Site
Lodz, 91-034
Novartis Investigative Site
Lodz, 91-347
Novartis Investigative Site
Myszków, 42-300
Novartis Investigative Site
Olsztyn, 10-165
Novartis Investigative Site
Piotrkow Trybunalski, 97-300
Novartis Investigative Site
Rzeszów, 35-055
Novartis Investigative Site
Tarnów, 33-100
Novartis Investigative Site
Torun, 87-100
Novartis Investigative Site
Warsaw, 00-215
Novartis Investigative Site
Wroclaw, 52-416
Novartis Investigative Site
Wroclaw, 53-673
Slovakia26 sites
Novartis Investigative Site
Bardejov, 085 01
Novartis Investigative Site
Bratislava, Slovak Republic, 841 04
Novartis Investigative Site
Bratislava, 813 69
Novartis Investigative Site
Bratislava, 831 01
Novartis Investigative Site
Bratislava, 831 06
Novartis Investigative Site
Bratislava, 833 05
Novartis Investigative Site
Bratislava, 833 48
Novartis Investigative Site
Bratislava, 841 08
Novartis Investigative Site
Bratislava, 851 01
Novartis Investigative Site
Dolný Kubín, 026 01
Novartis Investigative Site
Košice, 040 01
Novartis Investigative Site
Košice, 040 11
Novartis Investigative Site
Kráľovský Chlmec, 077 01
Novartis Investigative Site
Ľubochňa, 034 91
Novartis Investigative Site
Lučenec, Slovak Republic, 984 01
Novartis Investigative Site
Lučenec, 984 01
Novartis Investigative Site
Malacky, 901 22
Novartis Investigative Site
Nitra, 949 01
Novartis Investigative Site
Nitra, 949 11
Novartis Investigative Site
Nitra, 950 01
Novartis Investigative Site
Nové Zámky, 940 01
Novartis Investigative Site
Prešov, 080 01
Novartis Investigative Site
Rožňava, 048 01
Novartis Investigative Site
Šamorín, 931 01
Novartis Investigative Site
Svidník, 089 01
Novartis Investigative Site
Trnava, 917 01
France25 sites
Novartis Investigative Site
Avignon, 84000
Novartis Investigative Site
Besançon, 25030
Novartis Investigative Site
Béziers, 34525
Novartis Investigative Site
Bobigny, 93009
Novartis Investigative Site
Bordeaux, 33075
Novartis Investigative Site
Caen, 14033
Novartis Investigative Site
Compiègne, 60321
Novartis Investigative Site
Dijon, 21000
Novartis Investigative Site
Marseille, 13005
Novartis Investigative Site
Montauban, 82017
Novartis Investigative Site
Montpellier, 34295
Novartis Investigative Site
Nantes, 44093
Novartis Investigative Site
Nice, 06202
Novartis Investigative Site
Orléans, 45100
Novartis Investigative Site
Paris, 75012
Novartis Investigative Site
Paris, 75013
Novartis Investigative Site
Paris, 75015
Novartis Investigative Site
Paris, 75018
Novartis Investigative Site
Poitiers, 86021
Novartis Investigative Site
Rouen, 76031
Novartis Investigative Site
Strasbourg, 67091
Novartis Investigative Site
Tourcoing, 59208
Novartis Investigative Site
Valenciennes, 59300
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54511
Novartis Investigative Site
Villeneuve-d'Ascq, 59650
Netherlands22 sites
Novartis Investigative Site
's-Hertogenbosch, North Brabant, 5223 GZ
Novartis Investigative Site
Amsterdam, North Holland, 1090 HM
Novartis Investigative Site
Amsterdam, North Holland, 1105 AZ
Novartis Investigative Site
Arnhem, Gelderland, 6815 AD
Novartis Investigative Site
Beverwijk, North Holland, 1942 LE
Novartis Investigative Site
Delft, South Holland, 2625 AD
Novartis Investigative Site
Deventer, Overijssel, 7416 SE
Novartis Investigative Site
Dirksland, South Holland, 3247 BW
Novartis Investigative Site
Doetinchem, Gelderland, 7009 BL
Novartis Investigative Site
Dordrecht, South Holland, 3318 AT
Novartis Investigative Site
Ede, 6716 RP
Novartis Investigative Site
Eindhoven, 5623 EJ
Novartis Investigative Site
Enschede, 7512 KZ
Novartis Investigative Site
Gouda, 2803 HH
Novartis Investigative Site
Hardenberg, 7770 SE
Novartis Investigative Site
Leeuwarden, Provincie Friesland, 8934 AD
Novartis Investigative Site
Nijmegen, Gerlderland, 6532 SZ
Novartis Investigative Site
Nijmegen, 6525 GA
Novartis Investigative Site
Sneek, Provincie Friesland, 8601 ZK
Novartis Investigative Site
The Hague, South Holland, 2545 AA
Novartis Investigative Site
Tilburg, North Brabant, 5042 AD
Novartis Investigative Site
Venlo, 5912 BL
Colombia18 sites
Novartis Investigative Site
Barranquilla, Atlántico, 080002
Novartis Investigative Site
Barranquilla, Atlántico, 080012
Novartis Investigative Site
Barranquilla, Atlántico, 080020
Novartis Investigative Site
Barranquilla, Colombia, 080020
Novartis Investigative Site
Bogotá, 110221
Novartis Investigative Site
Bucaramanga, Santander Department, 681017
Novartis Investigative Site
Cali, Valle del Cauca Department, 760001
Novartis Investigative Site
Cali, 760042
Novartis Investigative Site
Chía, Cundinamarca, 250001
Novartis Investigative Site
Floridablanca, Santander Department, 691001
Novartis Investigative Site
Ibague, Tolima Department, 730006
Novartis Investigative Site
Manizales, 170008
Novartis Investigative Site
Medellín, Antioquia, 050010
Novartis Investigative Site
Medellín, Antioquia, 050021
Novartis Investigative Site
Medellín, 050012
Novartis Investigative Site
Medellín, 050034
Novartis Investigative Site
Medellín, 050037
Novartis Investigative Site
San Gil, 684031
Bulgaria17 sites
Novartis Investigative Site
Blagoevgrad, 2700
Novartis Investigative Site
Burgas, Burgas, 8000
Novartis Investigative Site
Burgas, 8001
Novartis Investigative Site
Gabrovo, 5300
Novartis Investigative Site
Kyustendil, 2500
Novartis Investigative Site
Pleven, 5800
Novartis Investigative Site
Plovdiv, 4002
Novartis Investigative Site
Sandanski, 2800
Novartis Investigative Site
Sofia, Bulgaria, 1202
Novartis Investigative Site
Sofia, 1233
Novartis Investigative Site
Sofia, 1504
Novartis Investigative Site
Sofia, 1510
Novartis Investigative Site
Sofia, 1606
Novartis Investigative Site
Sofia, 1750
Novartis Investigative Site
Stara Zagora, 6000
Novartis Investigative Site
Varna, 9010
Novartis Investigative Site
Veliko Tarnovo, 5000
Hungary17 sites
Novartis Investigative Site
Balatonfüred, 8230
Novartis Investigative Site
Budapest, Pest County, 1132
Novartis Investigative Site
Budapest, 1036
Novartis Investigative Site
Budapest, 1083
Novartis Investigative Site
Budapest, 1097
Novartis Investigative Site
Budapest, 1132
Novartis Investigative Site
Budapest, 1134
Novartis Investigative Site
Budapest, 1145
Novartis Investigative Site
Debrecen, 4027
Novartis Investigative Site
Hatvan, 3000
Novartis Investigative Site
Hosszúhetény, 7694
Novartis Investigative Site
Mosanmagyarovar, 9200
Novartis Investigative Site
Nyíregyháza, 4400
Novartis Investigative Site
Pécs, 7623
Novartis Investigative Site
Szeged, 6725
Novartis Investigative Site
Szekszárd, 7100
Novartis Investigative Site
Zalaegerszeg, Zala County, 8900
Turkey (Türkiye)15 sites
Novartis Investigative Site
Ankara, Bilkent-Cankaya, 06800
Novartis Investigative Site
Ankara, Sihhiye Altindag, 06230
Novartis Investigative Site
Denizli, Kinikli, 20070
Novartis Investigative Site
Eskişehir, Odunpazari, 26040
Novartis Investigative Site
Gaziantep, Sehitkamil, 27310
Novartis Investigative Site
Istanbul, Fatih, 34098
Novartis Investigative Site
Istanbul, Kadikoy, 34668
Novartis Investigative Site
Istanbul, Kucukcekmece, 34303
Novartis Investigative Site
Istanbul, Zeytinburnu, 34010
Novartis Investigative Site
Izmir, Balcova, 35340
Novartis Investigative Site
Izmir, Bayrakli, 35540
Novartis Investigative Site
Izmir, 35100
Novartis Investigative Site
Kayseri, Melikgazi, 38039
Novartis Investigative Site
Mersin, Yenisehir, 33110
Novartis Investigative Site
Muğla, Mentese, 48000
Australia13 sites
Novartis Investigative Site
Adelaide, South Australia, 5000
Novartis Investigative Site
Auchenflower, Queensland, 4066
Novartis Investigative Site
Camperdown, New South Wales, 2050
Novartis Investigative Site
Clayton, Victoria, 3168
Novartis Investigative Site
Concord, New South Wales, 2139
Novartis Investigative Site
Garran, Australian Capital Territory, 2605
Novartis Investigative Site
Heidelberg, Victoria, 3084
Novartis Investigative Site
Hobart, Tasmania, 7000
Novartis Investigative Site
Joondalup, Western Australia, 6027
Novartis Investigative Site
Leabrook, South Australia, 5068
Novartis Investigative Site
Malvern East, Victoria, 3145
Novartis Investigative Site
Sippy Downs, Queensland, 4556
Novartis Investigative Site
Woolloongabba, Queensland, 4102
Croatia13 sites
Novartis Investigative Site
Krapinske Toplice, Croatia, 49217
Novartis Investigative Site
Krapinske Toplice, 49217
Novartis Investigative Site
Opatija, 51410
Novartis Investigative Site
Osijek, County of Osijek-Baranja, 31000
Novartis Investigative Site
Osijek, 31000
Novartis Investigative Site
Pula, 52100
Novartis Investigative Site
Rijeka, Primorje-Gorski Kotar County, 51000
Novartis Investigative Site
Slavonski Brod, Croatia, 35000
Novartis Investigative Site
Varaždin, Varaždin County, 42000
Novartis Investigative Site
Vinkovci, 32100
Novartis Investigative Site
Zagreb, City of Zagreb, 10000
Novartis Investigative Site
Zagreb, Croatia, 10000
Novartis Investigative Site
Zagreb, 10000
Malaysia13 sites
Novartis Investigative Site
Alor Star, Kedah, 05460
Novartis Investigative Site
Ipoh, Perak, 30450
Novartis Investigative Site
Johor Bahru, 80100
Novartis Investigative Site
Kota Bharu, Kelantan, 16150
Novartis Investigative Site
Kuala Lumpur, Kuala Lumpur, 50586
Novartis Investigative Site
Kuala Lumpur, 50400
Novartis Investigative Site
Kuching, Sarawak, 93586
Novartis Investigative Site
Miri, Sarawak, 98000
Novartis Investigative Site
Seremban, Negeri Sembilan, 70300
Novartis Investigative Site
Seri Manjung, Perak, 32040
Novartis Investigative Site
Sungai Buloh, Selangor, 47000
Novartis Investigative Site
Taiping, Perak, 34000
Novartis Investigative Site
Timur Laut, Pulau Pinang, 11500
South Africa12 sites
Novartis Investigative Site
Bloemfontein, Free State, 9301
Novartis Investigative Site
Cape Town, Western Cape, 7500
Novartis Investigative Site
Cape Town, Western Cape, 7530
Novartis Investigative Site
Cape Town, ZAF, 7570
Novartis Investigative Site
Cape Town, 7531
Novartis Investigative Site
George, Western Cape, 6529
Novartis Investigative Site
KwaDukuza, KwaZulu-Natal, 4449
Novartis Investigative Site
Port Elizabeth, Eastern Cape, 6001
Novartis Investigative Site
Pretoria, Gauteng, 0184
Novartis Investigative Site
Pretoria, 0181
Novartis Investigative Site
Somerset West, Western Cape, 7130
Novartis Investigative Site
Western Cape, 7130
Denmark10 sites
Novartis Investigative Site
Aarhus N, 8200
Novartis Investigative Site
Copenhagen S, 2300
Novartis Investigative Site
Esbjerg, 6700
Novartis Investigative Site
Gandrup, 9362
Novartis Investigative Site
Herlev, 2730
Novartis Investigative Site
Herning, 7400
Novartis Investigative Site
Kobenhavn N V, 2400
Novartis Investigative Site
Roskilde, 4000
Novartis Investigative Site
Svendborg, 5700
Novartis Investigative Site
Vejle, 7100
Israel10 sites
Novartis Investigative Site
Beersheba, 8457108
Novartis Investigative Site
Haifa, 3104802
Novartis Investigative Site
Holon, Gush Dan, 5845997
Novartis Investigative Site
Jerusalem, 9112001
Novartis Investigative Site
Nahariya, 2210001
Novartis Investigative Site
Poria – Neve Oved, 1528001
Novartis Investigative Site
Ramat Gan, 5265601
Novartis Investigative Site
Rehovot, 7661041
Novartis Investigative Site
Sefad, 1311300
Novartis Investigative Site
Tel Aviv, 6423906
Lithuania10 sites
Novartis Investigative Site
Alytus, LT-62386
Novartis Investigative Site
Kaunas, Kaunas County, LT-50161
Novartis Investigative Site
Kaunas, Kaunas County, LT-50177
Novartis Investigative Site
Kaunas, LT-49449
Novartis Investigative Site
Kaunas, LT-50009
Novartis Investigative Site
Klaipėda, Klaipėda County, LT-91131
Novartis Investigative Site
Klaipėda, Klaipėda County, LT-92288
Novartis Investigative Site
Panevezys, LT-35144
Novartis Investigative Site
Šiauliai, LT-76206
Novartis Investigative Site
Vilnius, LT-08406
Portugal10 sites
Novartis Investigative Site
Almada, 2805-267
Novartis Investigative Site
Carnaxide, 2799-523
Novartis Investigative Site
Coimbra, 3004-561
Novartis Investigative Site
Lisbon, 1500-650
Novartis Investigative Site
Lisbon, 1649-035
Novartis Investigative Site
Matosinhos Municipality, 4454-513
Novartis Investigative Site
Porto, 4200-319
Novartis Investigative Site
Santa Maria da Feira, 4520-211
Novartis Investigative Site
Setúbal, 2910-549
Novartis Investigative Site
Vila Nova de Gaia, 4434-502
Taiwan9 sites
Novartis Investigative Site
Changhua, 50006
Novartis Investigative Site
Kaohsiung City, 80756
Novartis Investigative Site
Taichung, Taiwan ROC, 40201
Novartis Investigative Site
Taichung, 40447
Novartis Investigative Site
Tainan, 704
Novartis Investigative Site
Tainan, 71004
Novartis Investigative Site
Taipei, 110
Novartis Investigative Site
Taipei, 11217
Novartis Investigative Site
Taoyuan, 33305
Greece8 sites
Novartis Investigative Site
Athens, 115 21
Novartis Investigative Site
Athens, 115 27
Novartis Investigative Site
Athens, 151 23
Novartis Investigative Site
Heraklion Crete., 715 00
Novartis Investigative Site
Ioannina, 455 00
Novartis Investigative Site
Thessaloniki, 546 42
Novartis Investigative Site
Thessaloniki, 564 03
Novartis Investigative Site
Thessaloniki, 570 01
Estonia7 sites
Novartis Investigative Site
Pärnu, 80018
Novartis Investigative Site
Tallinn, 10128
Novartis Investigative Site
Tallinn, 10138
Novartis Investigative Site
Tallinn, 13419
Novartis Investigative Site
Tallinn, 13619
Novartis Investigative Site
Tartu, Estonia, 50406
Novartis Investigative Site
Tartu, 50708
Latvia7 sites
Novartis Investigative Site
Daugavpils, LV-5417
Novartis Investigative Site
Kuldīga, LV-3300
Novartis Investigative Site
Liepāja, LV 3401
Novartis Investigative Site
Ogre, LV-5001
Novartis Investigative Site
Riga, LV-1001
Novartis Investigative Site
Riga, LV-1002
Novartis Investigative Site
Riga, LV-1038
Sweden7 sites
Novartis Investigative Site
Gothenburg, 405 45
Novartis Investigative Site
Linköping, 582 13
Novartis Investigative Site
Lund, 222 21
Novartis Investigative Site
Solna, 171 64
Novartis Investigative Site
Stockholm, 111 57
Novartis Investigative Site
Uppsala, 75237
Novartis Investigative Site
Västerås, 721 89
Thailand7 sites
Novartis Investigative Site
Bangkok, 10330
Novartis Investigative Site
Bangkok, 10400
Novartis Investigative Site
Bangkok, 10700
Novartis Investigative Site
Chiang Mai, 50200
Novartis Investigative Site
Khon Kaen, THA, 40002
Novartis Investigative Site
Muang, Thailand, 12120
Novartis Investigative Site
Songkhla, Hat Yai, 90110
Belgium5 sites
Novartis Investigative Site
Aalst, Oost Vlaanderen, 9300
Novartis Investigative Site
Dendermonde, 9200
Novartis Investigative Site
Genk, Limburg, 3600
Novartis Investigative Site
Hasselt, Limburg, 3500
Novartis Investigative Site
Mechelen, 2800
Philippines5 sites
Novartis Investigative Site
Iloilo City, Iloilo, 5000
Novartis Investigative Site
Manila, National Capital Region, 1000
Novartis Investigative Site
Manila, 1000
Novartis Investigative Site
Quezon, 1102
Novartis Investigative Site
San Juan City, 1502
Switzerland5 sites
Novartis Investigative Site
Basel, 4031
Novartis Investigative Site
Bern, 3010
Novartis Investigative Site
Geneva, 1211
Novartis Investigative Site
Lucerne, 6000
Novartis Investigative Site
Lugano, 6900
Austria4 sites
Novartis Investigative Site
Braunau am Inn, 5280
Novartis Investigative Site
Graz, 8036
Novartis Investigative Site
Linz, 4021
Novartis Investigative Site
Vienna, 1190
Hong Kong4 sites
Novartis Investigative Site
Hong Kong, Hong Kong, 999077
Novartis Investigative Site
Hong Kong SAR, 999077
Novartis Investigative Site
Kowloon, 999077
Novartis Investigative Site
Shatin, 999077
Singapore4 sites
Novartis Investigative Site
Singapore, Singapore, 768828
Novartis Investigative Site
Singapore, 119074
Novartis Investigative Site
Singapore, 169608
Novartis Investigative Site
Singapore, 529889
Vietnam2 sites
Novartis Investigative Site
Hanoi, 100000
Novartis Investigative Site
Ho Chi Minh City, 700000
About this study
Official title: A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.
Read the detailed description
The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the risk of 4P-MACE in adult patients at high risk for their first major adverse cardiovascular event.
Randomized participants will receive study medication (inclisiran or placebo), administered s.c. on Day 1, Day 90, then every 6 months thereafter. This is an event-driven study. Therefore, the study will continue until the required number of clinical events have occurred across both treatment arms, and all participants have a minimum of 3 years of follow-up during the double-blind treatment period.
- Being tested
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
- Keywords
- Inclisiran, PCSK9, primary prevention, cardiovascular disease, MACE, myocardial infarction, stroke, LDL-C, hyperlipidemia, hypercholesterolemia, dyslipidemia, cholesterol, Coronary Artery Disease (CAD), Non-Obstructive Coronary Artery Disease (NOCAD), Coronary Artery Calcium, Coronary artery stenosis, Coronary angiogram
- Medical subject headings
- Cardiovascular Diseases, Myocardial Infarction, Stroke, Hyperlipidemias, Hypercholesterolemia, Dyslipidemias, Coronary Artery Disease, Coronary Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLDrug
Also called KJX839
Subcutaneous injection in pre-filled syringe.
Placebo in 1.5mlDrug
Matching placebo in 1.5ml solution for injection
| Study group | Role | What they receive |
|---|---|---|
| Inclisiran sodium 300mg | Experimental | Inclisiran sodium 300 mg in 1.5 mL solution for injection (subcutaneous) in pre-filled syringe.
Randomized in a 1:1 ratio with matching placebo Receives: Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL |
| Placebo | Placebo comparator | Matching placebo in 1.5ml pre-filled syringe. Randomized in a 1:1 ratio with Inclisiran. Receives: Drug: Placebo in 1.5ml |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to the first occurrence of 4P-MACE
4-Point-Major Adverse Cardiovascular Events (4P-MACE): composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization.
Measured: Time to the first occurrence of 4P-MACE (up to approximately 75 months)
Secondary outcomes (5)
Time to the first occurrence of 3P-MACE
3-Point-Major Adverse Cardiovascular Events (3P-MACE): composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke)
Measured: Time to the first occurrence of 3P-MACE (up to approximately 75 months)
Total number of first or repeated CV events (4P MACE)
Total 4P-MACE (composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization)
Measured: up to 75 months
Total number of first or repeated CV events (3P MACE)
Total 3P-MACE (composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke)
Measured: up to 75 months
Time to occurrence of Cardiovascular death
CV death is defined as death due to cardiovascular events.
Measured: Time to Cardiovascular death (up to 75 months)
Time to occurrence of death due to any reason
All-cause mortality is death due to any reason.
Measured: Time to all-cause mortality (up to 75 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2023
- Study start9 Mar 2023
- Primary completion16 Apr 2029 (estimated)
- Study completion16 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary Prevention of Atherosclerotic Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 14,012 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05739383
- Sponsor's protocol ID
- CKJX839D12302
- Status last verified
- Nov 2026
- First submitted
- 13 Feb 2023
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
- ClinicalTrials.gov ID
- NCT05739383
- Acronym / sponsor ID
- CKJX839D12302
- Keywords
- Inclisiran, PCSK9, primary prevention, cardiovascular disease, MACE, myocardial infarction, stroke, LDL-C
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 14,012 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 9 Mar 2023 (actual)
- Primary completion
- 16 Apr 2029 (estimated)
- Study completion
- 16 Apr 2029 (estimated)
- First posted
- 22 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.
Detailed description
The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the risk of 4P-MACE in adult patients at high risk for their first major adverse cardiovascular event.
Randomized participants will receive study medication (inclisiran or placebo), administered s.c. on Day 1, Day 90, then every 6 months thereafter. This is an event-driven study. Therefore, the study will continue until the required number of clinical events have occurred across both treatment arms, and all participants have a minimum of 3 years of follow-up during the double-blind treatment period.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Inclisiran sodium 300mg | Experimental | Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLInclisiran sodium 300 mg in 1.5 mL solution for injection (subcutaneous) in pre-filled syringe. Randomized in a 1:1 ratio with matching placebo |
| Placebo | Placebo comparator | Drug: Placebo in 1.5mlMatching placebo in 1.5ml pre-filled syringe. Randomized in a 1:1 ratio with Inclisiran. |
Who may qualify
- Ages
- 40 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- At an increased risk for a first MACE (i.e., no prior major ASCVD event), defined as any one of the following:
- LDL-C ≥70 mg/dL (≥1.81 mmol/L) but <190 mg/dL (<4.91 mmol/L) at the screening visit. If on a background lipid lowering therapy, the dose should be stable for at least 4 weeks prior to the screening visit and the participant should be willing to remain on this background therapy for the entire duration of the study.
Key exclusion criteria (9 listed)
- History of major ASCVD event.
- History of, or planned, ischemia-driven revascularization in a coronary or extracoronary arterial bed prior to randomization
- Absence of coronary atherosclerosis on a CT angiogram or an invasive coronary angiogram in the 2 years prior to randomization
- Coronary artery calcium (CAC) score of 0 obtained in the 2 years prior to randomization
- Active liver disease or hepatic dysfunction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLAlso: KJX839Subcutaneous injection in pre-filled syringe. | Drug | Inclisiran sodium 300mg |
| Placebo in 1.5mlMatching placebo in 1.5ml solution for injection | Drug | Placebo |
Primary outcome
Time to the first occurrence of 4P-MACE
Time frame: Time to the first occurrence of 4P-MACE (up to approximately 75 months)
4-Point-Major Adverse Cardiovascular Events (4P-MACE): composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization.
5 secondary outcomes
Time to the first occurrence of 3P-MACE
Time frame: Time to the first occurrence of 3P-MACE (up to approximately 75 months)
Total number of first or repeated CV events (4P MACE)
Time frame: up to 75 months
Total number of first or repeated CV events (3P MACE)
Time frame: up to 75 months
Time to occurrence of Cardiovascular death
Time frame: Time to Cardiovascular death (up to 75 months)
Time to occurrence of death due to any reason
Time frame: Time to all-cause mortality (up to 75 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: Yes. Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Related trials for Primary Prevention of Atherosclerotic Cardiovascular Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
RecruitingPhase 2
Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM), Atherosclerosis
Active, not recruitingObservational study
DETECTion of the Prevalence of Silent Atherosclerosis Across Adult Life - Phase I of REACT
Atherosclerosis, Subclinical Atherosclerosis
Active, not recruiting
Strategy for Unstable Coronary Plaque in Patients Presenting to Emergency Department for Chest Pain Suspected of Coronary Artery Disease
Atherosclerosis
RecruitingPhase 4
ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography
Cardiovascular Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
983 sites in 42 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL in people with Primary Prevention of Atherosclerotic Cardiovascular Disease, run by Novartis Pharmaceuticals at 983 sites in 42 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 983 sites in United States, Spain, United Kingdom, Argentina, China and 37 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to the first occurrence of 4P-MACE (time frame: Time to the first occurrence of 4P-MACE (up to approximately 75 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.